Close Menu

CHICAGO (GenomeWeb) – Cancer informatics and precision medicine company Tempus said today that it has landed $200 million in a Series F investment round. This new round brings the four-year-old firm's total venture capital to $520 million and valuation to $3.1 billion.

Series F investors include Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, Revolution Growth, and T. Rowe Price. With the investment, Novo Holdings Director Robert Ghenchev has joined the Tempus board of directors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.